Shree Ganesh Biotech (India) Ltd (SHREEGANES) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Shree Ganesh Biotech (India) Ltd on NSE and BSE, with an AI summary of each filing.
PFA
Others (Uncategorized) · 02 Nov 2026, 11:01 pm
Shree Ganesh Biotech Reports Nil Unutilised Issue Proceeds as of Sep'26 Shree Ganesh Biotech (India) Limited disclosed under Regulation 32(1) of SEBI LODR Regulations that it has no unutilised funds remaining as of 30th Sep'26, or as of 2nd Nov'26, from any previous public issues, rights issues, preferential issues, or Qualified Institutional Placements (QIPs). Consequently, no statement of deviation or variation under Annexure-A is required to be submitted to the stock exchanges.
PFA
Financial Result · 02 Nov 2026, 10:58 pm
Shree Ganesh Bio-Tech Reports Q2 FY27 Net Loss Amid Revenue Drop Shree Ganesh Bio-Tech (India) Ltd reported revenue from operations of ₹16.00 lakh for the quarter ended 30th Sep'26, falling 79.15% YoY from ₹76.74 lakh and 88.81% QoQ from ₹142.99 lakh. Total income reached ₹48.28 lakh, supported by ₹32.27 lakh in other income. Total expenses stood at ₹56.36 lakh, leading to a net loss of ₹8.08 lakh compared to a net profit of ₹1.41 lakh in Q2 FY26. For H1 FY27, revenue reached ₹158.99 lakh with a net loss of ₹65.40 lakh.
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 02 Nov 2026, 10:53 pm
Shree Ganesh Biotech (India) Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 16.0 (-79.2% YoY | -88.8% QoQ) ■ EBITDA: -40.4 (-1.9% YoY | +54.8% QoQ) ■ EBITDA Margin (%): -252 (-20058 bps YoY | -18971 bps QoQ) ■ PAT: -8.1 (Profit to Loss YoY | +85.9% QoQ) ■ EPS (INR): 0.00 (Loss to Profit QoQ)
Shree Ganesh Biotech (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 02 Nov 2026, 5:30 am
Shree Ganesh Bio-Tech Boards to Consider Q2 Results Shree Ganesh Bio-Tech (India) Limited has scheduled a meeting of its Board of Directors on 2nd Nov'26. The board will primarily consider, approve, and take on record the company's unaudited financial results for the second quarter and half-year ended 30th Sep'26, alongside other general corporate matters.
PFA
Annual General Meeting · 28 Sept 2026, 11:12 pm
Shree Ganesh Bio-Tech Shareholders Approve FY26 Financials and Director Re-Appointment Shree Ganesh Bio-Tech (India) Limited declared voting results for its 16th AGM held on 28th Sep'26. Public non-institutional shareholders cast 6.74M votes (1.69% of outstanding shares), with zero promoter or institutional participation. Shareholders approved the adoption of FY26 audited financial statements with 94.90% votes in favor (6.40M votes) versus 5.10% against (343,508 votes). Additionally, the ordinary resolution for the re-appointment of retiring director Aman Patel passed with 94.77% approval (6.39M votes in favor, 352,328 against).
PFA
Annual General Meeting · 28 Sept 2026, 11:06 pm
Shree Ganesh Bio-Tech Shareholders Approve FY26 Financials and Director Re-Appointment Shree Ganesh Bio-Tech (India) Limited concluded its 16th Annual General Meeting on 28th Sep'26. Shareholders approved ordinary resolutions for the adoption of audited financial statements for the fiscal year ended 31st Mar'26, alongside reports of the Directors and Auditors. Additionally, the re-appointment of Mr. Aman Patel as a director, who retired by rotation, was formally passed. Detailed voting results pursuant to Regulation 44(3) of SEBI Listing Regulations are being submitted separately.
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Others (Uncategorized) · 03 Sept 2026, 5:27 pm
PFA
Annual General Meeting · 03 Sept 2026, 4:56 pm
PFA
Others (Uncategorized) · 01 Sept 2026, 10:58 pm
Shree Ganesh Bio-Tech Announces New Corporate Website Shree Ganesh Bio-Tech (India) Limited announced an update to its corporate website on 01 Sep'26. The new website is now live at www.shreeganeshbiotech.bar. The company has requested stock exchanges, including BSE (Scrip: 539470), Calcutta Stock Exchange (Scrip: 29221), and Metropolitan Stock Exchange (Scrip: SHREEGANES), to update their records with the new web address and remove the old details. This change impacts the company's official online presence and information portal for investors and stakeholders.
PFA
Others (Uncategorized) · 04 Aug 2026, 9:52 pm
Shree Ganesh Bio-Tech Confirms Nil Unutilized Funds from Past Issues Shree Ganesh Bio-Tech (India) Limited informed exchanges on 04 Aug'26 that it has no unutilized funds remaining as of 30 Jun'26. This disclosure, under SEBI Regulation 32(1), confirms that all proceeds from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP) have been fully utilized. Consequently, the company stated that no deviation or variation statement is required. This update provides clarity on the company's capital allocation and completion of previously funded objectives.
PFA
Financial Result · 04 Aug 2026, 9:48 pm
Shree Ganesh Bio-Tech Reports Q1FY27 Net Loss Amidst Higher Expenses Shree Ganesh Bio-Tech reported a net loss of Rs. 57.32 lacs for Q1FY27 (quarter ended 30-Jun-26), a significant decline from a net profit of Rs. 32.70 lacs in Q1FY26. Total income decreased 2.7% YoY to Rs. 175.00 lacs, while total expenses surged 57.8% YoY to Rs. 232.32 lacs, driven primarily by a 66.7% rise in material costs. Consequently, the company recorded a loss before tax of Rs. 57.32 lacs, reversing a profit of Rs. 32.70 lacs YoY. EPS for the quarter was negative at Rs. (0.01).
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 04 Aug 2026, 9:45 pm
Shree Ganesh Biotech (India) Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lacs) ■ Revenue: 143 (+3.3% YoY | -32.6% QoQ) ■ EBITDA: -89.3 (-911.7% YoY | -110.3% QoQ) ■ EBITDA Margin (%): -62.5 (-5609 bps YoY | -4245 bps QoQ) ■ PAT: -57.3 (Profit to Loss YoY | -283.9% QoQ) ■ EPS (INR): -0.01 (Profit to Loss YoY)
Shree Ganesh Biotech (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 04 Aug 2026, 5:30 am
Shree Ganesh Bio-Tech Board to Approve Q1FY27 Results on 4th Aug'26 Shree Ganesh Bio-Tech (India) Limited has scheduled a Board of Directors meeting for 4th Aug'26. The primary agenda is to consider and approve the Un-Audited Financial Results for the first quarter ending 30th Jun'26.
PFA
Others (Uncategorized) · 14 May 2026, 11:19 pm
Shree Ganesh Bio-Tech Confirms Full Utilization of Past Fund-Raising Proceeds Shree Ganesh Bio-Tech (India) Limited filed a disclosure on 14 May'26, confirming compliance with SEBI's regulations on the use of funds. The company stated it has no unutilized funds remaining as of 31 Mar'26 from any past public issue, rights issue, preferential issue, or Qualified Institutional Placement (QIP). As all proceeds have been fully utilized, no statement of deviation or variation was required or provided. This confirms that capital raised in the past has been completely deployed.
PFA
Financial Result · 14 May 2026, 11:11 pm
SHREE GANESH BIO-TECH (INDIA) LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 212 (-29.4% YoY | +203.9% QoQ) ■ EBITDA: -42.5 (+69.9% YoY | -775.7% QoQ) ■ EBITDA Margin (%): -20.0 (+2691 bps YoY | -1307 bps QoQ) ■ PAT: -14.9 (+84.2% YoY | Profit to Loss QoQ) ■ EPS (INR): 0.00 (Loss to Profit YoY | -100.0% QoQ)
This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Outcome · 14 May 2026, 11:07 pm
SHREE GANESH BIO-TECH (INDIA) LIMITED - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 212 (-29.4% YoY | +203.9% QoQ) ■ EBITDA: -42.5 (+69.9% YoY | -775.7% QoQ) ■ EBITDA Margin (%): -20.0 (+2691 bps YoY | -1307 bps QoQ) ■ PAT: -14.9 (+84.2% YoY | Profit to Loss QoQ) ■ EPS (INR): 0.00 (Loss to Profit YoY | -100.0% QoQ)
Shree Ganesh Biotech (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 14 May 2026, 5:30 am
Shree Ganesh Bio-Tech Board Meeting to Approve FY26 Results Shree Ganesh Bio-Tech (India) Ltd. has scheduled a Board of Directors meeting for 14 May'26. The primary agenda is to consider and approve the audited standalone financial results for the quarter and fiscal year ended 31 Mar'26. The board will also take on record the accompanying auditors' report. Any other matters may be discussed with the board's permission. This meeting is crucial for the release of the company's Q4 and full-year earnings.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 23 Apr 2026, 11:51 pm
Shree Ganesh Bio-Tech Confirms It Is Not a "Large Corporate" Shree Ganesh Bio-Tech (India) Limited confirmed on 23-Apr'26 that it does not qualify as a "Large Corporate" under the SEBI framework for debt security fundraising. This exemption means the company is not required to furnish the initial and annual disclosures mandated by the circular for the financial year ending 31-Mar'26. The filing indicates the company had zero outstanding borrowings and no credit rating in the previous financial year, supporting its non-classification as a Large Corporate.
PFA
Others (Uncategorized) · 29 Jan 2026, 10:01 pm
Shree Ganesh Bio-Tech Confirms Full Utilization of Past Fundraising Proceeds Shree Ganesh Bio-Tech (India) Limited filed a disclosure on 29 Jan'26, pursuant to SEBI's Regulation 32(1). The company confirmed it had no unutilized funds remaining as of 31 Dec'25, from any proceeds of past public issues, rights issues, preferential issues, or qualified institutional placements (QIPs). This declaration indicates that all capital raised previously has been fully deployed, with no deviation or variation from stated objectives requiring disclosure.
PFA
Financial Result · 29 Jan 2026, 9:57 pm
Shree Ganesh Bio-Tech Q3FY26 Net Profit Rises Sharply Sequentially Shree Ganesh Bio-Tech reported Q3FY26 results for the period ended 31 Dec’25. Revenue from operations stood at ₹69.81 lakh, a 9.0% QoQ decline but a significant drop from ₹1,441.18 lakh YoY. Profit after tax saw a substantial sequential increase to ₹32.23 lakh from ₹1.41 lakh in the prior quarter, though it marked a 58.2% YoY decrease. Expenses were sharply lower at ₹74.67 lakh compared to ₹1,394.43 lakh YoY, driving the improved sequential profitability. EPS for the quarter was ₹0.01.
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 29 Jan 2026, 9:43 pm
SHREE GANESH BIO-TECH (INDIA) LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakh) ■ Revenue: 69.8 (-95.2% YoY | -9.0% QoQ) ■ EBITDA: -4.9 (Profit to Loss YoY | +87.8% QoQ) ■ EBITDA Margin (%): -6.9 (Profit to Loss YoY | +4466 bps QoQ) ■ PAT: 32.2 (-58.2% YoY | +2185.8% QoQ) ■ EPS (INR): 0.01 (-50.0% YoY)
Shree Ganesh Biotech (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 29 Jan 2026, 5:30 am
Shree Ganesh Bio-Tech Sets Board Meeting for Q3 FY26 Results Shree Ganesh Bio-Tech (India) Ltd. announced a Board of Directors meeting scheduled for 29th Jan '26. The primary agenda is to consider and approve the un-audited financial results for the quarter and nine months ending on 31st Dec '25. The meeting will also address any other matters with the board's permission. This intimation complies with Regulation 29 of SEBI (LODR) Regulations, 2015.
PFA
Others (Uncategorized) · 08 Nov 2025, 10:01 pm
PFA
Financial Result · 08 Nov 2025, 9:56 pm
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 08 Nov 2025, 9:52 pm